Drugs subject to Price Disclosure - 1 February 2025
Page last updated: 1 February 2025
This page lists those drugs where a brand of a pharmaceutical item is subject to Price Disclosure requirements and identifies the next Reduction Day for those drugs.
Each cycle of Price Disclosure is identified, for consistency and clarity, by the reduction day. For example, the first reduction day under the Originator Removal amendments was the 2016 October Cycle, the second was the 2017 April Cycle, followed by the 2017 October Cycle, etc.
Data is collected for each drug and manner of administration (drug/MoA) throughout the year. For example, for drug/MoAs that are included in the 2024 April cycle, data was collected from 1 April 2023 to 30 September 2023 and for the 2024 October cycle, data will be collected from 1 October 2023 to 31 March 2024. Data is required to be submitted on 11 November and 12 May each year, six weeks after the end of the relevant data collection period.
The Department intends to publish outcomes for:
- April cycles - mid to late December of the previous year; and
- October cycles - mid to late June of the same year.
Drugs Subject to Price Disclosure - 1 February 2025 (XLSX 23KB)
Note:
- From 1 May 2024 the Drugs subject to Price Disclosure list will be provided as an Excel file.
- Changes for this month are highlighted.
- Some drug names have changed in July 2018 as a result of the Therapeutic Goods Administration’s International Harmonisation of Ingredient Names reform to bring medicine ingredient names in line with international nomenclature. These changes will have no material impact on the Price Disclosure program. For easy reference, medicines with name changes are indicated with a number in the Legislative Instrument Drug Name column in the table below, with the corresponding endnote describing the change to that medicine.
